BRIEF—Verastem to present key Phase II update at ASCO 2023

Boston, USA-based Verastem Oncology will present updated interim results from Part A of the Phase II RAMP 201 study of avutometinib and defactinib at this year’s annual meeting of the American Society of Clinical Oncology (ASCO).

The trial tests the combo in certain people with low-grade serous ovarian carcinoma (LGSOC) - a type of cancer with limited treatment options, for which chemo is the current standard of care.

Verastem will test the combination in Part B of the study.

The company is in discussions with the US regulator on confirmatory study plans and intends to provide an update after an agreement with the agency is reached.

Chief executive Brian Stuglik said: “Building on our breakthrough therapy designation, we are pleased with the continued progress of our LGSOC program and look forward to the presentation of these updated results from the RAMP 201 trial at ASCO 2023.”